Last updated on November 2017

A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLEBLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)


Brief description of study

A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLEBLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)

Detailed Study Description

CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)

Clinical Study Identifier: TX11187

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jay Dobson

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »